Loading
Life sciences · Journal article
Chemistry & Biodiversity · August 1, 2026
Raises a question worth testing. It does not answer one.
This is a narrative review of ethnopharmacological and medicinal chemistry literature on plant-based agents against infectious diseases. It identifies over 150 medicinal plants and their phytochemical constituents (alkaloids, terpenoids, flavonoids, phenolics, saponins) with reported in vitro anti-infective mechanisms, but explicitly notes the lack of standardization, bioavailability limitations, and insufficient clinical trials as barriers to translation.
Narrative literature review. Traditional medicinal plants used across ethnic systems; no human study population reported..
Over 150 medicinal plants used historically for infectious disease treatment identified across traditional Chinese medicine, Ayurveda, and Unani systems. Key phytochemical classes (alkaloids, terpenoids, flavonoids, phenolics, saponins) demonstrate broad-spectrum anti-infective activity via membrane damage, enzyme inhibition, oxidative stress, and nucleic acid interference. Examples of validated ethnopharmacology–pharmacology integration: artemisinin, berberine, andrographolide, and glycyrrhizin.
Source does not report clinical trial data, efficacy endpoints, or safety outcomes in humans. Examples of validated ethnopharmacology–pharmacology integration: artemisinin, berberine, andrographolide, and glycyrrhizin.
This review suggests that ethnopharmacological approaches may identify lead candidates for anti-infective drug development amid rising antimicrobial resistance. However, clinicians and researchers should note that the evidence base remains largely preclinical; clinical translation requires rigorous standardization, bioavailability optimization, and well-designed clinical trials before therapeutic recommendations can be made.
A narrative review synthesizing ethnopharmacological and medicinal chemistry literature to identify plant-derived candidates for anti-infective development; raises mechanistic and therapeutic questions rather than testing hypotheses in humans or animals.
As stated by the source record.
Quoted from the source exactly as published.
This review suggests that ethnopharmacological approaches may identify lead candidates for anti-infective drug development amid rising antimicrobial resistance. However, clinicians and researchers should note that the evidence base remains largely preclinical; clinical translation requires rigorous standardization, bioavailability optimization, and well-designed clinical trials before therapeutic recommendations can be made.
Graded across the dimensions that decide whether you should act, each from what the source actually supports. There is no single score, and where a dimension was not assessed it says so.
Infectious diseases are traditionally managed using medicinal herbs in traditional Chinese medicine, Ayurveda and Unani. These conventional therapies are an essential source of new anti-infective drugs considering antimicrobial resistance threatens global public health. The present review critically appraises the use of medicinal plants against bacterial, viral, fungal and parasitic infections in combination with medicinal chemistry and ethnopharmacology. A comprehensive review of ethnobotanical data, phytochemistry and pharmacological studies was performed on the basis of WHO classification of infectious diseases in order to identify repeating medicinal plants and their active ingredients. Over 150 medicinal plants have been discovered by major ethnomedical systems in the course of history and have been used as the remedy of infectious diseases. Essential phytochemicals such as alkaloids, terpenoids, flavonoids, phenolics and saponins showed broad-spectrum anti-infective activity via mechanisms including membrane damage, enzyme inhibition, oxidative stress regulation and interference with nucleic acid synthesis. Some examples of such successful combination of ethnopharmacology with pharmacology include artemisinin, berberine, andrographolide and glycyrrhizin. Nevertheless, the lack of standardization, poor bioavailability and insufficient clinical trials are still problematic.
Taken from the source record, never inferred. Follow any of these and new work involving them reaches your briefing.